<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>我的项目主页</title>
    <link rel="stylesheet" href="style.css">
</head>
<body>
    <header>
        <h1>欢迎来到Jiangnan-China Drylab主页</h1>

    </header>

    <main>
        <h2>Drylab项目介绍</h2>


        <section class="project">
            <h3>引言：双刃剑般的免疫分子——人源抗菌肽LL-37</h3>
            <p>在人体复杂而精密的免疫防御网络中，存在一类古老而高效的效应分子——抗菌肽（Antimicrobial Peptides, AMPs）。其中，LL-37是迄今为止在人类体内发现的唯一隶属于cathelicidin家族的成员，堪称人体抵御病原体入侵的第一道防线的“明星分子”。它的命名源于其氨基酸序列的显著特征：N-端由两个亮氨酸（Leucine, 简写为L）起始，且全长共由37个氨基酸残基构成。LL-37并非以活性形式直接存在于细胞中。它的前体是无活性的hCAP18蛋白（human Cationic Antimicrobial Protein, 18 kDa），主要储存在中性粒细胞、巨噬细胞以及皮肤、呼吸道和消化道的上皮细胞的颗粒中。当机体遭遇感染或组织损伤时，炎症信号会触发细胞释放hCAP18。随后，由中性粒细胞等免疫细胞分泌的蛋白酶3（Proteinase 3）等酶类会像一把精准的剪刀，切掉hCAP18蛋白的前段，从而释放出具有强大生物活性的LL-37肽段。</p>
            <a href="#">查看详情</a>
        </section>

        <section class="project">
            <h3>Introduction: The Double-Edged Sword of Immunity – Human Antimicrobial Peptide LL-37</h3>
            <p>Within the complex and sophisticated immune defense network of the human body, there exists an ancient and highly efficient class of effector molecules known as Antimicrobial Peptides (AMPs). Among them, LL-37 is, to date, the only member of the cathelicidin family found in humans, making it a "star molecule" in the body's first line of defense against pathogenic invasion. Its name originates from its distinct sequence features: it begins with two Leucine (L) residues at its N-terminus and comprises a total of 37 amino acid residues. LL-37 does not exist in its active form within cells. Its precursor is the inactive hCAP18 protein (human Cationic Antimicrobial Protein, 18 kDa), which is primarily stored in the granules of neutrophils, macrophages, and epithelial cells of the skin, respiratory tract, and digestive tract. When the body encounters an infection or tissue injury, inflammatory signals trigger the release of hCAP18. Subsequently, enzymes such as Proteinase 3, secreted by immune cells like neutrophils, act like precise molecular scissors, cleaving the N-terminal fragment of the hCAP18 protein to release the potently bioactive LL-37 peptide.</p>
            <a href="#">查看详情</a>
        </section>






        <section class="project">
            <h3></h3>
            <p>LL-37的生物学功能远超“抗菌”二字，它是一柄双刃剑，兼具直接杀伤和免疫调控的双重作用：1. 直接、广谱的病原体清除能力：作为一种阳离子肽，LL-37带有正电荷，能够被细菌、真菌等病原体细胞膜上带负电荷的磷脂成分强烈吸引。一旦结合，它会像楔子一样插入并破坏膜的完整性，通过形成“地毯模型”或“环孔模型”等机制在膜上打孔，导致细胞内容物泄漏，最终使病原体迅速裂解死亡。尤为重要的是，这种物理性的杀伤机制使得细菌很难产生耐药性，因此LL-37对包括耐甲氧西林金黄色葡萄球菌（MRSA）在内的多种超级耐药菌都表现出优异的杀伤效果。2. 复杂而强大的免疫调节功能：除了直接杀敌，LL-37更像一位战场指挥官。它能够趋化并招募中性粒细胞、单核细胞、T细胞等免疫细胞向感染部位聚集；调节炎症因子的释放，在感染初期促进炎症以清除病原，而在后期又能抑制过度炎症，防止组织损伤；此外，它还能促进血管新生、刺激上皮细胞增殖与迁移，从而加速伤口愈合。</p>
            <a href="#">查看详情</a>
        </section>

                <section class="project">
            <h3></h3>
            <p>The biological functions of LL-37 extend far beyond mere "antimicrobial" activity; it is a double-edged sword, possessing dual roles of direct killing and immunomodulation: 1. Direct, Broad-Spectrum Pathogen Elimination: As a cationic peptide, LL-37 carries a positive charge, allowing it to be strongly attracted to the negatively charged phospholipid components of pathogen cell membranes, such as those of bacteria and fungi. Upon binding, it inserts itself like a wedge, disrupting membrane integrity by forming pores through mechanisms like the "carpet model" or "toroidal pore model." This leads to the leakage of cellular contents and ultimately, rapid lysis and death of the pathogen. Crucially, this physical mechanism of killing makes it difficult for bacteria to develop resistance, enabling LL-37 to exhibit excellent efficacy against various multidrug-resistant superbugs, including Methicillin-resistant Staphylococcus aureus (MRSA). 2. Complex and Potent Immunomodulatory Functions: Beyond direct pathogen destruction, LL-37 acts more like a field commander. It can chemoattract and recruit immune cells such as neutrophils, monocytes, and T-cells to the site of infection; it modulates the release of inflammatory cytokines, promoting inflammation in the early stages to clear pathogens while suppressing excessive inflammation later to prevent tissue damage. Furthermore, it promotes angiogenesis (new blood vessel formation) and stimulates the proliferation and migration of epithelial cells, thereby accelerating wound healing.</p>
            <a href="#">查看详情</a>
        </section>








        <section class="project">
            <h3>困境：从理想价值到现实应用的巨大鸿沟</h3>
            <p>尽管LL-37的潜力巨大，但将其从实验室的研究对象转变为可供大众使用的产品，却面临着一道难以逾越的生产鸿沟。首先，天然提取路径被完全阻断。LL-37在人体内的浓度极低，通常处于纳摩尔至微摩尔级别，且其释放是瞬时和局部的。试图从血液或组织中分离纯化以满足商业需求，无异于大海捞针，成本和技术难度之高使其在经济和实践上都毫无可行性，更不用说涉及到的伦理问题。其次，化学合成的成本高到令人望而却步。目前实验室级别的LL-37主要通过固相多肽合成法（SPPS）制备。对于一个长达37个氨基酸的多肽，这意味着需要至少36步偶联反应。即便每一步的反应效率都高达99.5%，最终的理论总产率也仅为83.5%左右。在实际操作中，不可避免地会产生大量错误序列。这导致后续的纯化工作（通常是高效液相色谱法HPLC）变得异常繁重，不仅耗时耗力，还会进一步大幅拉低最终的有效产率。因此，化学合成一克高纯度LL-37的成本可高达数千甚至数万美元，这使得其应用被死死限制在小剂量的科学研究上。</p>
            <a href="#">查看详情</a>
        </section>


        <section class="project">
            <h3>The Dilemma: A Vast Chasm Between Ideal Value and Real-World Application</h3>
            <p>Despite LL-37's immense potential, transforming it from a laboratory subject into a publicly available product faces an insurmountable production gap. Firstly, the path of natural extraction is completely blocked. The concentration of LL-37 in the human body is extremely low, typically in the nanomolar to micromolar range, and its release is transient and localized. Attempting to isolate and purify it from blood or tissues to meet commercial demand is akin to finding a needle in a haystack; the high cost and technical difficulty make it entirely infeasible economically and practically, not to mention the associated ethical issues. Secondly, the cost of chemical synthesis is prohibitively high. Currently, lab-grade LL-37 is primarily produced via Solid-Phase Peptide Synthesis (SPPS). For a 37-amino-acid peptide, this entails at least 36 coupling steps. Even with a high step-wise efficiency of 99.5%, the final theoretical yield is only about 83.5%. In practice, the process inevitably generates numerous incorrect sequences, making the subsequent purification work (typically via High-Performance Liquid Chromatography, HPLC) extraordinarily cumbersome. This is not only time-consuming and labor-intensive but also further drastically reduces the final effective yield. Consequently, the cost to chemically synthesize one gram of high-purity LL-37 can reach thousands or even tens of thousands of dollars, severely restricting its use to small-scale scientific research.</p>
            <a href="#">查看详情</a>
        </section>





        <section class="project">
            <h3>探索：生物合成的尝试与新的挑战</h3>
            <p>为了打破成本僵局，我们自然而然地将目光投向了现代生物技术的核心——重组蛋白表达，即利用工程化的微生物作为“细胞工厂”来生产LL-37。我们选择了酿酒酵母（Saccharomyces cerevisiae）作为表达宿主。选择它的理由非常充分：它具有“公认安全”（GRAS）的地位，拥有成熟的大规模工业发酵技术体系，并且作为真核生物，其蛋白加工机制更接近人类。然而，这条看似光明的道路同样布满荆棘。我们的初步实验证实，直接在酿酒酵母中表达野生型的LL-37，效果远不尽人意，主要暴露出三大核心问题：1. 对宿主的细胞毒性：LL-37的膜破坏机制不分敌我，它在杀死细菌的同时，也会对生产它自身的酿酒酵母的细胞膜造成损伤，导致酵母生长缓慢、表达量低下甚至死亡。2. 固有的不稳定性：LL-37肽链本身对蛋白酶敏感，在应用环境中（如伤口渗出液）会被迅速降解失活。3. 部分条件下活性受限：野生型LL-37的活性在生理条件（如高盐浓度）下会受到抑制。</p>
            <a href="#">查看详情</a>
        </section>
        <section class="project">
            <h3>Exploration: The Foray into Biosynthesis and Its Emerging Challenges</h3>
            <p>To break the cost barrier, we naturally turned to the core of modern biotechnology—recombinant protein expression, using engineered microorganisms as "cell factories" to produce LL-37. We selected Saccharomyces cerevisiae\ (baker's yeast) as the expression host. The reasons for this choice are compelling: it holds "Generally Recognized as Safe" (GRAS) status, benefits from mature, large-scale industrial fermentation technologies, and, as a eukaryote, its protein processing machinery is closer to that of humans. However, this promising path proved to be fraught with its own challenges. Our initial experiments confirmed that directly expressing the wild-type LL-37 in yeast was far from satisfactory, revealing three core problems: 1. Cytotoxicity to the Host: LL-37's membrane-disrupting mechanism is indiscriminate; while killing bacteria, it also damages the cell membranes of the yeast producing it, leading to slow growth, low expression levels, or even cell death. 2. Inherent Instability: The LL-37 peptide chain is inherently susceptible to proteases and would be rapidly degraded and inactivated in an application environment (e.g., wound exudate). 3. Limited Activity Under Certain Conditions: The activity of wild-type LL-37 is inhibited under physiological conditions, such as high salt concentrations.</p>
            <a href="#">查看详情</a>
        </section>









        <section class="project">
            <h3>解决方案与模型介绍</h3>
            <p>我们的模型是一个集成了多种先进算法的复合框架，其核心优势在于能够精准、高效地探索LL-37的序列空间，并预测新序列的功能特性。模型的具体构成和工作流程如下：

1. ESM2 (Evolutionary Scale Modeling 2) 深度表征模块: 我们首先使用强大的蛋白质语言模型ESM2对LL-37的序列进行编码。ESM2能够将LL-37序列转化为一个信息丰富的数学向量（embedding），为后续的生成和预测提供高质量的特征输入。
2. Diffusion (扩散) 生成模型模块: 在获得LL-37的深度特征后，我们采用先进的生成式AI技术——扩散模型，来创造新的序列变体。它以ESM2提供的特征为引导，生成大量新颖且具有高潜力的候选变体序列。
3. Mamba 高效预测与筛选模块: 生成海量候选序列后，我们引入了最新的Mamba架构。Mamba能够以线性的计算复杂度高效处理序列，我们利用它构建了一个高效的预测器，它能够迅速评估由扩散模型生成的每一个LL-37变体的关键性能指标，如稳定性（抗蛋白酶降解能力）、抗菌活性和毒性等。</p>
            <a href="#">查看详情</a>
        </section>
        <section class="project">
            <h3>Solution & Model</h3>
            <p>Our model is a composite framework that integrates several advanced algorithms. Its core advantage lies in its ability to precisely and efficiently explore the sequence space of LL-37 and predict the functional properties of new sequences. The specific components and workflow of the model are as follows:

1. ESM2 (Evolutionary Scale Modeling 2) Deep Representation Module: We first use the powerful protein language model, ESM2, to encode the LL-37 sequence. ESM2 transforms the sequence into an information-rich mathematical vector (embedding), providing a high-quality feature input for subsequent generation and prediction.
2. Diffusion Model Generation Module: After obtaining the deep features of LL-37, we employ an advanced generative AI technology—the Diffusion model—to create new sequence variants. Guided by the features provided by ESM2, it generates a vast number of novel and high-potential candidate variant sequences.
3. Mamba Efficient Prediction and Screening Module: After generating a massive number of candidate sequences, we introduce the latest Mamba architecture. Mamba can efficiently process sequences with linear computational complexity. We leverage it to build an efficient predictor that can rapidly evaluate key performance indicators for each LL-37 variant generated by the Diffusion model, such as stability (resistance to proteolysis), antimicrobial activity, and toxicity.</p>
            <a href="#">查看详情</a>
        </section>






        



    </main>

    <footer>
        <p>你可以在 <a href="https://github.com/你的GitHub用户名">GitHub</a> 联系我们。</p>
    </footer>
</body>
</html>